LOS ANGELES, CA--(Marketwired - Jan 28, 2014) - Hanover Portfolio Acquisitions, (OTCQB: HVPA) has announced that it will now operate under the name Endonovo Therapeutics, effective immediately.
As part of the move, the Company's website (www.hanoverpai.com) has changed to www.endonovo.com and soon the Company email addresses will migrate to @endonovo.com suffix.
The Company is adopting the name Endonovo Therapeutics to coincide with the development of its non-invasive, Time-Varying Electromagnetic Field ("TVEMF") therapies for inflammatory, autoimmune and degenerative diseases including diabetes, liver and cardiovascular disease.
The Company's technology can mobilize and expand stem cells 80-fold to therapeutic levels and up-regulate hundreds of components involved in the healing/regeneration process without the use of drugs.
"We started developing the technology at NASA in the 1980's to create therapies for diseases and injuries that astronauts might experience during long term manned missions in outer space," said Dr. Donnie Rudd, Chief Scientist and Director of IP at Endonovo Therapeutics. "We are now looking to apply what we have learned over last 25 years about the effects of microgravity and the earth's magnetic field on specific cells to treat diseases here on earth."
"The change from Hanover Portfolio Acquisitions to Endonovo Therapeutics comes at a defining point in our company's history," said Alan Collier, CEO. "We have independent third-party studies that confirm the safety of our technology. The next step is to conduct clinical trials to prove the efficacy of our technology in treating several diseases."
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a biotechnology company developing non-invasive electromagnetic therapies designed to extend and enhance the human life by regenerating tissues and organs that have become injured or damaged by disease and age. Endonovo is developing therapies for various inflammatory, autoimmune and degenerative diseases using Time-Varying Electromagnetic Fields (TVEMF) developed at NASA. The Company's business model includes the international licensing of its stem cell mobilization and expansion technologies and the development of non-invasive electromagnetic therapies.
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.